Drug Type Synthetic peptide |
Synonyms |
Target |
Mechanism Kv1.3 blockers(Voltage-gated potassium channel subunit Kv1.3 blockers), T lymphocytes modulators |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Autoimmune Diseases | Phase 1 | NL | - | - |
Inflammatory Bowel Diseases | Phase 1 | US | - | - |
Lupus Nephritis | Phase 1 | US | - | - |
Multiple Sclerosis | Phase 1 | US | - | - |
Myositis, Inclusion Body | Phase 1 | US | - | |
Obesity | Phase 1 | US | - | |
Plaque psoriasis | Phase 1 | US | - | |
Vasculitis | Phase 1 | US | - | - |
Phase 1 | 24 | (rwupzygtwi) = The most common adverse events were temporary mild (Grade 1) hypoesthesia (n = 20; 75% placebo, 85% dalazatide) and paresthesia (n = 15; 25% placebo, 70% dalazatide) involving the hands, feet, or perioral area. pfwjxiohjg (wdrsfkcrho ) | Positive | 19 Jul 2017 | |||
Placebo | |||||||
Phase 1 | Plaque psoriasis CD4 | CD8 | - | (wypffgdmej) = The treatment was well tolerated with all subjects completing the study and reporting only mild adverse events idtwypzznf (pfjzltnhai ) | Positive | 09 Nov 2015 |